|
1
|
Trickey A, Sabin CA, Burkholder G, Crane
H, d'Arminio Monforte A, Egger M, Gill MJ, Grabar S, Guest JL,
Jarrin I, et al: Life expectancy after 2015 of adults with HIV on
long-term antiretroviral therapy in Europe and North America: A
collaborative analysis of cohort studies. Lancet HIV. 10:e295–e307.
2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Marino A, Zafarana G, Ceccarelli M,
Cosentino F, Moscatt V, Bruno G, Bruno R, Benanti F, Cacopardo B
and Celesia BM: Immunological and clinical impact of DAA-Mediated
HCV Eradication in a Cohort of HIV/HCV Coinfected Patients:
Monocentric Italian Experience. Diagnostics (Basel).
11(2336)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
D'Andrea F, Venanzi Rullo E, Marino A,
Moscatt V, Celesia BM, Cacopardo B, Condorelli F, La Rocca G, Di
Rosa M, Pellicanò GF, et al: Hepatitis B virus infection and
hepatocellular carcinoma in PLWH: Epidemiology, pathogenesis and
treatment. World Cancer Res J. 7(e1537)2020.
|
|
4
|
Peters E and Iwuji AC: Efficacy, safety
and tolerability of Biktarvy in HIV-1 infection: A scoping review.
Antivir Ther. 28(13596535231159030)2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Celesia BM, Marino A, del Vecchio RF,
Bruno R, Palermo F, Gussio M, Nunnari G and Cacopardo B: Is it Safe
and Cost Saving to Defer the CD4+ cell count monitoring in stable
patients on art with more than 350 or 500 cells/µl? Mediterr J
Hematol Infect Dis. 11(e2019063)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Celesia BM, Marino A, Borracino S,
Arcadipane AF, Pantò G, Gussio M, Coniglio S, Pennisi A, Cacopardo
B and Panarello G: Successful extracorporeal membrane oxygenation
treatment in an acquired immune deficiency syndrome (AIDS) patient
with acute respiratory distress syndrome (ARDS) Complicating
Pneumocystis jirovecii Pneumonia: A Challenging Case. Am J Case
Rep. 21(e919570)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Micali C, Russotto Y, Facciolà A, Marino
A, Celesia BM, Pistarà E, Caci G, Nunnari G, Pellicanò GF and
Venanzi Rullo E: Pulmonary kaposi sarcoma without respiratory
symptoms and skin lesions in an HIV-Naïve Patient: A case report
and literature review. Infect Dis Rep. 14:228–242. 2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ambrosioni J, Levi L, Alagaratnam J, Van
Bremen K, Mastrangelo A, Waalewijn H, Molina JM, Guaraldi G,
Winston A, Boesecke C, et al: Major revision version 12.0 of the
European AIDS Clinical Society guidelines 2023. HIV Med.
24:1126–1136. 2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Marino A, Cosentino F, Ceccarelli M,
Moscatt V, Pampaloni A, Scuderi D, D'Andrea F, Rullo EV, Nunnari G,
Benanti F, et al: Entecavir resistance in a patient with
treatment-naïve HBV: A case report. Mol Clin Oncol.
14(113)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Marino A, Pavone G, Martorana F, Fisicaro
V, Motta L, Spampinato S, Celesia BM, Cacopardo B, Vigneri P and
Nunnari G: Navigating the Nexus: HIV and Breast Cancer-A Critical
Review. Int J Mol Sci. 25(3222)2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ron R, Martínez-Sanz J, Herrera S,
Ramos-Ruperto L, Díez A, Sainz T, Álvarez-Díaz N, Correa-Pérez A,
Muriel A, López-Alcalde J, et al: CD4/CD8 ratio and CD8+ T-cell
count as prognostic markers for non-AIDS mortality in people living
with HIV. A systematic review and meta-analysis. Front Immunol.
15(1343124)2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Serrano-Villar S, Wu K, Hunt PW, Lok JJ,
Ron R, Sainz T, Moreno S, Deeks SG and Bosch RJ: Predictive value
of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in
the risk of AIDS and non-AIDS events. EBioMedicine.
80(104072)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
World Health Organization (WHO):
Consolidated guidelines on HIV prevention, testing, treatment,
service delivery and monitoring: Recommendations for a public
health approach. WHO, Geneva, 2021.
|
|
14
|
Baeten JM, Donnell D, Ndase P, Mugo NR,
Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira
E, et al: Antiretroviral prophylaxis for HIV prevention in
heterosexual men and women. N Engl J Med. 367:399–410.
2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Baeten JM, Kahle E, Lingappa JR, Coombs
RW, Delany-Moretlwe S, Nakku-Joloba E, Mugo NR, Wald A, Corey L,
Donnell D, et al: Genital HIV-1 RNA predicts risk of heterosexual
HIV-1 transmission. Sci Transl Med. 3(77ra29)2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Acosta RK, Willkom M, Andreatta K, Liu H,
Martin R, Parvangada A, Martin H, Collins S and White KL: Switching
to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From
Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate
(TDF) in the Presence of Pre-existing NRTI Resistance. J Acquir
Immune Defic Syndr. 85:363–371. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Chang HM, Chou PY, Chou CH and Tsai HC:
Outcomes After Switching to BIC/FTC/TAF in patients with
virological failure to protease inhibitors or non-nucleoside
reverse transcriptase inhibitors: A real-world cohort study. Infect
Drug Resist. 14:4877–4886. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chen LY, Sun HY, Chuang YC, Huang YS, Liu
WD, Lin KY, Chang HY, Luo YZ, Wu PY, Su YC, et al: Patient-reported
outcomes among virally suppressed people living with HIV after
switching to Co-formulated bictegravir, emtricitabine and tenofovir
alafenamide. J Microbiol Immunol Infect. 56:575–585.
2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Daar ES, DeJesus E, Ruane P, Crofoot G,
Oguchi G, Creticos C, Rockstroh JK, Molina JM, Koenig E, Liu YP, et
al: Efficacy and safety of switching to fixed-dose bictegravir,
emtricitabine, and tenofovir alafenamide from boosted protease
inhibitor-based regimens in virologically suppressed adults with
HIV-1: 48 week results of a randomised, open-label, multicentre,
phase 3, non-inferiority trial. Lancet HIV. 5:e347–e356.
2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
De Socio GV, Tordi S, Altobelli D, Gidari
A, Zoffoli A and Francisci D: Dolutegravir/Lamivudine versus
Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch
Strategy in a Real-Life Cohort of Virogically Suppressed People
Living with HIV. J Clin Med. 12(7759)2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hagins D, Kumar P, Saag M, Wurapa AK, Brar
I, Berger D, Osiyemi O, Hileman CO, Ramgopal MN, McDonald C, et al:
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in
Black Americans With HIV-1: A Randomized Phase 3b, Multicenter,
Open-Label Study. J Acquir Immune Defic Syndr. 88:86–95.
2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kityo C, Hagins D, Koenig E, Avihingsanon
A, Chetchotisakd P, Supparatpinyo K, Gankina N, Pokrovsky V,
Voronin E, Stephens JL, et al: Switching to Fixed-Dose Bictegravir,
Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically
Suppressed HIV-1 Infected Women: A Randomized, Open-Label,
Multicenter, Active-Controlled, Phase 3, Noninferiority Trial. J
Acquir Immune Defic Syndr. 82:321–328. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Knobel H, Cañas-Ruano E, Guelar A, Knobel
P, Villar-García J, González-Mena A, Canepa C, Arrieta-Aldea I,
Marcos A, Abalat-Torrres A and Güerri-Fernández R: Switching to
Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir
alafenamide. A comparative real-world study. HIV Res Clin Pract.
24(2239564)2023.PubMed/NCBI
|
|
24
|
Lake JE, Hyatt AN, Feng H, Debroy P,
Kettelhut A, Miao H, Peng L, Bhasin S, Bell S, Rianon N, et al: A
randomized clinical trial of transgender women switching to
B/F/TAF: The (mo)BETTA Trial. Open Forum Infect Dis.
10(ofad178)2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lazzaro A, Cacciola EG, Borrazzo C,
Innocenti GP, Cavallari EN, Mezzaroma I, Falciano M, Fimiani C,
Mastroianni CM, Ceccarelli G and d'Ettorre G: Switching to a
Bictegravir Single Tablet Regimen in Elderly People Living with
HIV-1: Data Analysis from the BICTEL Cohort. Diagnostics (Basel).
12(76)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lazzaro A, Bianchini D, Gentilini Cacciola
E, Mezzaroma I, Falciano M, Andreoni C, Fimiani C, Santinelli L,
Maddaloni L, Bugani G, et al: Immune Reconstitution and Safe
Metabolic Profile after the Switch to
Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among
Virologically Controlled PLWH: A 96 Week Update from the BICTEL
Cohort. Viruses. 15(1222)2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Maggiolo F, Rizzardini G, Molina JM,
Pulido F, De Wit S, Vandekerckhove L, Berenguer J, D'Antoni ML,
Blair C, Chuck SK, et al: Bictegravir/Emtricitabine/Tenofovir
Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65
Years: Week 48 Results of a Phase 3b, Open-Label Trial. Infect Dis
Ther. 10:775–788. 2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Molina JM, Ward D, Brar I, Mills A,
Stellbrink HJ, López-Cortés L, Ruane P, Podzamczer D, Brinson C,
Custodio J, et al: Switching to fixed-dose bictegravir,
emtricitabine, and tenofovir alafenamide from dolutegravir plus
abacavir and lamivudine in virologically suppressed adults with
HIV-1: 48 week results of a randomised, double-blind, multicentre,
active-controlled, phase 3, non-inferiority trial. Lancet HIV.
5:e357–e365. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tsai MS, Sun HY, Chen CP, Lee CH, Lee CY,
Liu CE, Tang HJ, Hung TC, Li CW, Lee YT, et al: Switching to
coformulated bictegravir, emtricitabine, and tenofovir alafenamide
maintained viral suppression in adults with historical virological
failures and K65N/R mutation. Int J Infect Dis. 126:39–47.
2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Rolle CP, Nguyen V, Patel K, Cruz D,
DeJesus E and Hinestrosa F: Real-world efficacy and safety of
switching to bictegravir/emtricitabine/tenofovir alafenamide in
older people living with HIV. Medicine (Baltimore).
100(e27330)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sax PE, Rockstroh JK, Luetkemeyer AF,
Yazdanpanah Y, Ward D, Trottier B, Rieger A, Liu H, Acosta R,
Collins SE, et al: Switching to bictegravir, emtricitabine, and
tenofovir alafenamide in virologically suppressed adults with human
immunodeficiency virus. Clin Infect Dis. 73:e485–e493.
2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Klatzmann D, Barré-Sinoussi F, Nugeyre MT,
Danquet C, Vilmer E, Griscelli C, Brun-Veziret F, Rouzioux C,
Gluckman JC, Chermann JC, et al: Selective tropism of
lymphadenopathy associated virus (LAV) for helper-inducer T
lymphocytes. Science. 225:59–63. 1984.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Doitsh G and Greene WC: Dissecting How CD4
T Cells Are Lost During HIV Infection. Cell Host Microbe.
19:280–291. 2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bishop JD, DeShields S, Cunningham T and
Troy SB: CD4 count recovery after initiation of antiretroviral
therapy in patients infected with human immunodeficiency virus. Am
J Med Sci. 352:239–244. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ho DD, Neumann AU, Perelson AS, Chen W,
Leonard JM and Markowitz M: Rapid turnover of plasma virions and
CD4 lymphocytes in HIV-1 infection. Nature. 373:123–126.
1995.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Roederer M, Dubs JG, Anderson MT, Raju PA
and Herzenberg LA and Herzenberg LA: CD8 naive T cell counts
decrease progressively in HIV-infected adults. J Clin Invest.
95:2061–2066. 1995.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Favre D, Stoddart CA, Emu B, Hoh R, Martin
JN, Hecht FM, Deeks SG and McCune JM: HIV disease progression
correlates with the generation of dysfunctional naive CD8(low) T
cells. Blood. 117:2189–2199. 2011.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Oxenius A, Price DA, Easterbrook PJ,
O'Callaghan CA, Kelleher AD, Whelan JA, Sontag G, Sewell AK and
Phillips RE: Early highly active antiretroviral therapy for acute
HIV-1 infection preserves immune function of CD8+ and CD4+ T
lymphocytes. Proc Natl Acad Sci USA. 97:3382–3387. 2000.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Badejo OA, Chang CC, So-Armah KA, Tracy
RP, Baker JV, Rimland D, Butt AA, Gordon AJ, Rinaldo CR Jr, Kraemer
K, et al: CD8+ T-Cells Count in Acute Myocardial Infarction in HIV
disease in a predominantly male cohort. Biomed Res Int.
2015(246870)2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Schneider S, Spinner CD, Cassese S, Promny
D, Hapfelmeier A, Byrne RA, Baumann M, Jäger H, Steinlechner E,
Laugwitz KL and Kastrati A: Association of increased CD8+ and
persisting C-reactive protein levels with restenosis in HIV
patients after coronary stenting. AIDS. 30:1413–1421.
2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Borges ÁH, Neuhaus J, Babiker AG, Henry K,
Jain MK, Palfreeman A, Mugyenyi P, Domingo P, Hoffmann C, Read TR,
et al: Immediate antiretroviral therapy reduces risk of
infection-related cancer during early HIV Infection. Clin Infect
Dis. 63:1668–1676. 2016.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Helleberg M, May MT, Ingle SM, Dabis F,
Reiss P, Fätkenheuer G, Costagliola D, d'Arminio A, Cavassini M,
Smith C, et al: Smoking and life expectancy among HIV-infected
individuals on antiretroviral therapy in Europe and North America.
AIDS. 29:221–229. 2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Castilho JL, Shepherd BE, Koethe J, Turner
M, Bebawy S, Logan J, Rogers WB, Raffanti S and Sterling TR:
CD4+/CD8+ ratio, age, and risk of serious non-communicable diseases
in HIV-infected adults on antiretroviral therapy. AIDS. 30:899–908.
2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Dock JN and Effros RB: Role of CD8 T cell
replicative senescence in human aging and in HIV-mediated
Immunosenescence. Aging Dis. 2:382–397. 2011.PubMed/NCBI
|
|
45
|
Avelino-Silva VI, Miyaji KT, Hunt PW,
Huang Y, Simoes M, Lima SB, Freire MS, Caiaffa-Filho HH, Hong MA,
Costa DA, et al: CD4/CD8 Ratio and KT Ratio Predict Yellow Fever
Vaccine Immunogenicity in HIV-Infected Patients. PLoS Negl Trop
Dis. 10(e0005219)2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Collin A, Le Marec F, Vandenhende MA,
Lazaro E, Duffau P, Cazanave C, Gérard Y, Dabis F, Bruyand M and
Bonnet F: ANRS CO3 Aquitaine Cohort Study Group. Incidence and risk
factors for severe bacterial infections in people living with HIV.
ANRS CO3 Aquitaine Cohort, 2000-2012. PLoS One.
11(e0152970)2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Vrinceanu D, Dumitru M, Patrascu OM,
Costache A, Papacocea T and Cergan R: Current diagnosis and
treatment of rhinosinusal aspergilloma (Review). Exp Ther Med.
22(1264)2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Saydam FN, Erdem H, Ankarali H, El-Arab
Ramadan ME, El-Sayed NM, Civljak R, Pshenichnaya N, Moroti RV,
Mahmuodabad FM, Maduka AV, et al: Vector-borne and zoonotic
infections and their relationships with regional and socioeconomic
statuses: An ID-IRI survey in 24 countries of Europe, Africa and
Asia. Travel Med Infect Dis. 44(102174)2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Sigel K, Wisnivesky J, Crothers K, Gordon
K, Brown ST, Rimland D, Rodriguez-Barradas MC, Gibert C, Goetz MB,
Bedimo R, et al: Immunological and infectious risk factors for lung
cancer in US veterans with HIV: A longitudinal cohort study. Lancet
HIV. 4:e67–e73. 2017.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Mujawar Z, Rose H, Morrow MP, Pushkarsky
T, Dubrovsky L, Mukhamedova N, Fu Y, Dart A, Orenstein JM,
Bobryshev YV, et al: Human immunodeficiency virus impairs reverse
cholesterol transport from macrophages. PLoS Biol.
4(e365)2006.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Lu L, Yang Y, Yang Z, Wu Y, Liu X, Li X,
Chen L, Han Y, Song X, Kong Z, et al: Altered plasma metabolites
and inflammatory networks in HIV-1 infected patients with different
immunological responses after long-term antiretroviral therapy.
Front Immunol. 14(1254155)2023.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Papantoniou E, Arvanitakis K, Markakis K,
Papadakos SP, Tsachouridou O, Popovic DS, Germanidis G, Koufakis T
and Kotsa K: Pathophysiology and clinical management of
dyslipidemia in people living with HIV: Sailing through Rough Seas.
Life (Basel). 14(449)2024.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Stanley TL and Grinspoon SK: Body
composition and metabolic changes in HIV-Infected Patients. J
Infect Dis. 205 (Suppl 3):S383–S390. 2012.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Avihingsanon A, Chetchotisakd P,
Kiertiburanakul S, Ratanasuwan W, Siripassorn K, Supparatpinyo K,
Martin H, Wang H, Wong T and Wang HY: Efficacy and safety of
switching to bictegravir, emtricitabine, and tenofovir alafenamide
in virologically suppressed Asian adults living with HIV: A pooled
analysis from three international phase III randomized trials. HIV
Med. 24:290–300. 2023.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Maggiolo F, Rizzardini G, Molina JM,
Pulido F, De Wit S, Vandekerckhove L, Berenguer J, D'Antoni ML,
Blair C, Chuck SK, et al: Bictegravir/emtricitabine/tenofovir
alafenamide in older individuals with HIV: Results of a 96-week,
phase 3b, open-label, switch trial in virologically suppressed
people ≥65 years of age. HIV Med. 24:27–36. 2023.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Squillace N, Ricci E, Maggi P, Taramasso
L, Menzaghi B, De Socio GV, Piconi S, Maurizio Celesia B, Orofino
G, Sarchi E, et al: Real-life safety of Emtricitabine/Tenofovir
Alafenamide/Bictegravir. PLoS One. 18(e0289132)2023.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Perrone RD, Madias NE and Levey AS: Serum
creatinine as an index of renal function: new insights into old
concepts. Clin Chem. 38:1933–1953. 1992.PubMed/NCBI
|
|
58
|
Kashani K, Rosner MH and Ostermann M:
Creatinine: From physiology to clinical application. Eur J Intern
Med. 72:9–14. 2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Ando M and Yanagisawa N: Epidemiology,
clinical characteristics, and management of chronic kidney disease
in human immunodeficiency virus-infected patients. World J Nephrol.
4:388–395. 2015.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Ryom L, Mocroft A, Kirk O, Worm SW, Kamara
DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, et al:
Association between antiretroviral exposure and renal impairment
among HIV-positive persons with normal baseline renal function: The
D:A:D study. J Infect Dis. 207:1359–1369. 2013.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Pottel H, Vrydags N, Mahieu B,
Vandewynckele E, Croes K and Martens F: Establishing age/sex
related serum creatinine reference intervals from hospital
laboratory data based on different statistical methods. Clin Chim
Acta. 396:49–55. 2008.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Yamada J, Tomiyama H, Yambe M, Koji Y,
Motobe K, Shiina K, Yamamoto Y and Yamashina A: Elevated serum
levels of alanine aminotransferase and gamma glutamyltransferase
are markers of inflammation and oxidative stress independent of the
metabolic syndrome. Atherosclerosis. 189:198–205. 2006.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Nixon DE and Landay AL: Biomarkers of
immune dysfunction in HIV. Curr Opin HIV AIDS. 5:498–503.
2010.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Siest G, Schiele F, Galteau MM, Panek E,
Steinmetz J, Fagnani F and Gueguen R: Aspartate aminotransferase
and alanine aminotransferase activities in plasma: statistical
distributions, individual variations, and reference values. Clin
Chem. 21:1077–1087. 1975.PubMed/NCBI
|
|
65
|
Sookoian S and Pirola CJ: Liver enzymes,
metabolomics and genome-wide association studies: From systems
biology to the personalized medicine. World J Gastroenterol.
21:711–725. 2015.PubMed/NCBI View Article : Google Scholar
|
